Navigation Links
EpiCept Accelerates Development of Phase I Clinical Study for Cancer

EpiCept Corporation today announced that with the initiation of a new study center, Tower Cancer Research Foundation in Los Angeles, it will accelerate the recruitment of patients in the currently ongoing Phase I clinical study of EPC2407, a novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. The first two cohorts of patients have been completed according to schedule at Scottsdale Healthcare Center. The third cohort is currently ongoing at Scottsdale Healthcare Center and at the University of California, Moores Cancer Center, San Diego.

EPC2407 belongs to a novel class of microtubulin inhibitors discovered by EpiCept. These compounds cause caspase activation, cell cycle arrest, and apoptotic death in cancer cells.

The Phase I trial of EPC2407 is now being conducted in three U.S. cancer centers and will administer increasing doses to small groups in approximately 30-40 patients with advanced stages of solid tumors. The primary objectives of the study are to determine the safety (maximum tolerated dose) and the pharmacokinetic profile of the drug. The study will also characterize the pharmacodynamic effects on tumor blood flow and identify early signs of objective anti-tumor response as measured by CT scans, MRI or PET, in these advanced cancer patients with well vascularized solid tumors.

Dr. Peter J. Rosen, Medical Director at Tower Cancer Research Foundation, stated, "Tower Oncology is very excited to work with EpiCept on the clinical development of EPC2407, a product with a new mechanistic approach, which could offer significant advantages in the fight against cancer."

EpiCept President and Chief Executive Officer Jack Talley commented, "We are pleased to be joined by Tower Cancer Research Foundation in the development of EPC2407 and we believe that their participation will result in our completing the trial ahead of p lan. We expect to be in a position to report the results of this important clinical trial later this year."

EPC2407 has shown promising vascular targeting activity with nanomolar potencies of anti-tumor activity in pre-clinical in vitro and in vivo studies. The molecule has been shown to induce tumor cell apoptosis and selectively inhibit growth of proliferating cell lines, including multi-drug resistant cell lines. Murine models of human tumor xenografts demonstrated EPC2407 inhibits growth of established tumors of a number of different cancer types more effectively than the other VDAs tested and was synergistic when used in combination with anticancer agents, such as Cisplatin. The combination of EPC2407 with other anticancer agents in a Phase 1b trial is planned to follow the current monotherapy trial. EPC2407 is one of two VDA compounds currently in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). The second compound, Azixa(TM), is part of the EP90745 series of apoptosis inducers, which was licensed by EpiCept to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement. Myriad recently announced that Azixa(TM) has a second mode of action due to vascular disruption activity (VDA). The compound is currently being evaluated in two Phase II human clinical trials, one in patients with primary brain cancer and the other in brain metastases due to melanoma. EpiCept's licensing agreement with Myriad for Azixa includes milestone payments, and sublicensing income as well as future royalties in the event Myriad's development of Azixa continues to progress successfully.
'"/>




Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Missing Protein In Cancer Development
4. Tomatoes Might Inhibit the Development Of Prostate Cancer
5. Pollution Found To Impair Lung Development
6. Treating Depression In Children Could Lead To Poor Bone Development
7. Developmental Origins of Polycystic Ovarian Syndrome
8. Sleep Not Critical For Early Brain Development Of Baby Dolphins
9. ‘Loud Noise’ Research may help in Development of Prosthetics for Eldery
10. Stop Watching TV: Toddler Development Affected
11. Vitamin Supplements During Pregnancy to Boost Fetal Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... NY (PRWEB) , ... May 26, 2016 , ... ... founder of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), ... and Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) Cancer ... this new partnership, OncLive’s editorial and marketing teams will publicize and promote public ...
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... 20 years of experience in leading technology and human resources operations for health ... teaching, Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is seeking nominations to serve on its Accreditation and Standards Committees and ... “RadSite’s quality-benchmarking activities incorporate key process and outcome measures, with the ultimate ...
(Date:5/26/2016)... , ... May 26, 2016 , ... According to the ... an industry filled with chemical-laden beauty products, one company is going against the norm ... you: Mad Hippie. The rising star in the green space is proud to announce ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)...   , ... primären Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung ... plus guter , Reinigung des ...      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... von der MORA-Studie der Phase III für NER1006 ...
Breaking Medicine Technology: